New AAD Guideline Seeks to Improve Awareness of Comorbidities Associated With Atopic Dermatitis
New AAD guidelines seek to raise awareness of comorbid disorders in patients with atopic dermatitis among dermatologists and other clinicians.
New AAD guidelines seek to raise awareness of comorbid disorders in patients with atopic dermatitis among dermatologists and other clinicians.
For patients with psoriasis, vitiligo, atopic dermatitis, and chronic urticaria, COVID-19 severity does not differ, but treatment of COVID-19 may affect the course of skin disease.
The relationship between air pollutants and atopic dermatitis is evaluated.
Clinicians report the cutaneous reactions experienced by healthcare workers who received the Pfizer COVID-19 vaccine.
The rates of SARS-CoV-2 infection, hospitalization, and mortality in patients with or without AD are compared.
The FDA has accepted for Priority Review the supplemental Biologics License Application (sBLA) for dupilumab as an add-on maintenance treatment for pediatric atopic dermatitis.
This study supports the use of dupilumab as a systemic treatment for long-term management of moderate to severe AD without routine laboratory monitoring in clinical practice.
The safety and efficacy profile from this study supports the role of dupilumab as continuous long-term treatment for patients with moderate to severe atopic dermatitis.
Although atopic dermatitis in infancy was not associated with later behavioral problems, at 6.5 years old, children who experienced asthma or atopic dermatitis symptoms within the past year were at increased risk for concomitant emotional problems.
Children with both atopic dermatitis and food allergy have stratum corneum abnormalities that distinguish them from other atopic dermatitis endotypes and children without atopic disease.